Back to top
more

National Vision (EYE)

(Delayed Data from NSDQ)

$10.04 USD

10.04
734,781

+0.07 (0.70%)

Updated Oct 11, 2024 04:00 PM ET

After-Market: $10.02 -0.02 (-0.20%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (73 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Urmimala Biswas headshot

Thermo Fisher Rides on New Product Suite and Global Growth

by Urmimala Biswas

A series of product launches with better precision medicine initiatives aids Thermo Fisher's (TMO) performance.

    EYE or NEOG: Which Is the Better Value Stock Right Now?

    by Zacks Equity Research

    EYE vs. NEOG: Which Stock Is the Better Value Option?

    ViewRay Allies With Two Majors in MR-Guided Radiation Therapy

    by Zacks Equity Research

    ViewRay's (VRAY) collective investments from Elekta and Medtronic are conditioned to the consummation of an equity capital hike of at least $75 million.

      RadNet Hits New 52-Week High: What's Driving the Stock?

      by Zacks Equity Research

      RadNet (RDNT) is optimistic about maintaining momentum on several positive developments.

      Hologic (HOLX) to Showcase Health Solutions Portfolio at RSNA

      by Zacks Equity Research

      Hologic (HOLX) to highlight its latest offerings in its breast health portfolio at the ongoing annual RSNA meet.

      BioSig Technologies Partners Mayo Clinic to Treat Arrhythmia

      by Zacks Equity Research

      BioSig Technologies (BSGM) signs agreement with Mayo Foundation for improving arrhythmia treatment along with covering therapies for autonomic nervous system disease.

      Here's Why You Should Invest in ResMed (RMD) Stock Right Now

      by Zacks Equity Research

      Investors continue to be optimistic about ResMed (RMD) on its stellar performance.

      National Vision Holdings, Inc. (EYE) Shares March Higher, Can It Continue?

      by Zacks Equity Research

      As of late, it has definitely been a great time to be an investor in National Vision Holdings, Inc. (EYE).

      Medtronic Displays All-Business-Line Growth Despite Cost Woes

      by Zacks Equity Research

      Medtronic's (MDT) Diabetes group is expanding internationally on the strong rollout of its MiniMed 670G in untapped markets.

      Hologic's LOCalizer RFID Tag in Breast Health Gets CE Mark

      by Zacks Equity Research

      Hologic (HOLX) wins the CE Mark for long-term use of LOCalizer RFID tag, providing more flexibility to breast-conserving surgery.

      QIAGEN and DiaSorin Get FDA Approval for LIAISON QFT-Plus

      by Zacks Equity Research

      QIAGEN (QGEN) and DiaSorin begin the commercial launch of the QFT-Plus test in the United States, following the FDA clearance.

      Neogen's (NEOG) Food Safety Test Receives AOAC Clearance

      by Zacks Equity Research

      Neogen's (NEOG) Reveal 3-D safety test for checking peanut contamination in food items gets approval from the AOAC.

      Bio-Rad's Blood Typing Market Growth Strong on New Products

      by Zacks Equity Research

      Bio-Rad's (BIO) new product acceptance in the United States is a positive with the recent 510(k) clearance of the IH-Reader 24.

      Amedisys (AMED) to Broaden Hospice Base With Asana Purchase

      by Zacks Equity Research

      Asana's acquisition to be the third hospice care buyout of Amedisys (AMED) in 2019.

      Medtronic Gets FDA Nod for IN.PACT AV for ESRD Patients

      by Zacks Equity Research

      Medtronic (MDT) receives FDA clearance for IN.PACT AV for the treatment of arteriovenous failures in patients undergoing hemodialysis.

      Here's Why You Should Buy Thermo Fisher (TMO) Stock Now

      by Zacks Equity Research

      Investors continue to be optimistic about Thermo Fisher (TMO) on its stellar performance.

      NuVasive Gets FDA Nod for CoRoent Small Interlock System

      by Zacks Equity Research

      NuVasive (NUVA) receives the FDA clearance for expanded use of its Interlock system for minimally disruptive spine surgery at multiple levels.

      Omnicell (OMCL) Rides on Global Expansion, Strategic R&Ds

      by Zacks Equity Research

      Omnicell's (OMCL) diligent focus on product innovation through R&D is encouraging.

      EYE vs. LMAT: Which Stock Is the Better Value Option?

      by Zacks Equity Research

      EYE vs. LMAT: Which Stock Is the Better Value Option?

      National Vision's (EYE) Q3 Earnings Top Estimates, View Raised

      by Zacks Equity Research

      National Vision's (EYE) third-quarter performance reflects strong growth in core business segments.

      National Vision (EYE) Tops Q3 Earnings and Revenue Estimates

      by Zacks Equity Research

      National Vision (EYE) delivered earnings and revenue surprises of 50.00% and 1.45%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

      National Vision (EYE) Reports Next Week: What You Should Expect

      by Zacks Equity Research

      National Vision (EYE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

      EYE vs. LMAT: Which Stock Should Value Investors Buy Now?

      by Zacks Equity Research

      EYE vs. LMAT: Which Stock Is the Better Value Option?

      GNC Holdings Inks Retail Partnership Deal to Grow in Brazil

      by Zacks Equity Research

      We consider this corporate deal in Brazil to be a strategic fit for GNC Holdings (GNC), which currently pulls out all the stops to fortify its global footprint.

      National Vision (EYE) Down 11.1% Since Last Earnings Report: Can It Rebound?

      by Zacks Equity Research

      National Vision (EYE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.